Literature DB >> 32038940

Importance of semaphorins in cancer immunity.

Li-Han Chen1, Eric Y Cuang1,2,3.   

Abstract

Entities:  

Year:  2019        PMID： 32038940      PMCID： PMC6987368          DOI： 10.21037/tlcr.2019.12.22

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  17 in total

1.  Immunosuppressive role of semaphorin-3A on T cell proliferation is mediated by inhibition of actin cytoskeleton reorganization.

Authors:  Yves Lepelletier; Ivan Cruz Moura; Réda Hadj-Slimane; Amédée Renand; Susana Fiorentino; Cédric Baude; Anat Shirvan; Ari Barzilai; Olivier Hermine
Journal:  Eur J Immunol       Date:  2006-07       Impact factor: 5.532

2.  Impeding macrophage entry into hypoxic tumor areas by Sema3A/Nrp1 signaling blockade inhibits angiogenesis and restores antitumor immunity.

Authors:  Andrea Casazza; Damya Laoui; Mathias Wenes; Sabrina Rizzolio; Nicklas Bassani; Marco Mambretti; Sofie Deschoemaeker; Jo A Van Ginderachter; Luca Tamagnone; Massimiliano Mazzone
Journal:  Cancer Cell       Date:  2013-12-09       Impact factor: 31.743

Review 3.  The regulatory role of semaphorin 3E in allergic asthma.

Authors:  Hesam Movassagh; Latifa Koussih; Lianyu Shan; Abdelilah S Gounni
Journal:  Int J Biochem Cell Biol       Date:  2018-11-15       Impact factor: 5.085

Review 4.  Tumor progression: the neuronal input.

Authors:  Marco Arese; Federico Bussolino; Margherita Pergolizzi; Laura Bizzozero; Davide Pascal
Journal:  Ann Transl Med       Date:  2018-03

5.  Semaphorin-3A is expressed by tumor cells and alters T-cell signal transduction and function.

Authors:  Alfonso Catalano; Paola Caprari; Simona Moretti; Monica Faronato; Luca Tamagnone; Antonio Procopio
Journal:  Blood       Date:  2005-12-27       Impact factor: 22.113

6.  Semaphorin 3A upregulates FOXO 3a-dependent MelCAM expression leading to attenuation of breast tumor growth and angiogenesis.

Authors:  R Mishra; D Thorat; G Soundararajan; S J Pradhan; G Chakraborty; K Lohite; S Karnik; G C Kundu
Journal:  Oncogene       Date:  2014-04-14       Impact factor: 9.867

Review 7.  Impact of semaphorin expression on prognostic characteristics in breast cancer.

Authors:  Ramesh Butti; Totakura Vs Kumar; Ramakrishna Nimma; Gopal C Kundu
Journal:  Breast Cancer (Dove Med Press)       Date:  2018-05-31

8.  The extracellular SEMA domain attenuates intracellular apoptotic signaling of semaphorin 6A in lung cancer cells.

Authors:  Cheng-Ying Shen; Ya-Chu Chang; Li-Han Chen; Wen-Chun Lin; Yung-Hua Lee; Shu-Tsen Yeh; Hsin-Kuang Chen; Wentao Fang; Chung-Ping Hsu; Jang-Ming Lee; Tzu-Pin Lu; Pei-Wen Hsiao; Liang-Chuan Lai; Mong-Hsun Tsai; Eric Y Chuang
Journal:  Oncogenesis       Date:  2018-12-05       Impact factor: 7.485

9.  The tumor suppressor semaphorin 3B triggers a prometastatic program mediated by interleukin 8 and the tumor microenvironment.

Authors:  Charlotte Rolny; Lorena Capparuccia; Andrea Casazza; Massimiliano Mazzone; Antonella Vallario; Alessandro Cignetti; Enzo Medico; Peter Carmeliet; Paolo M Comoglio; Luca Tamagnone
Journal:  J Exp Med       Date:  2008-05-05       Impact factor: 14.307

10.  Semaphorin 6A Attenuates the Migration Capability of Lung Cancer Cells via the NRF2/HMOX1 Axis.

Authors:  Li-Han Chen; Che-Yu Liao; Liang-Chuan Lai; Mong-Hsun Tsai; Eric Y Chuang
Journal:  Sci Rep       Date:  2019-09-16       Impact factor: 4.379
View more
  3 in total

Review 1.  Next generation of immune checkpoint inhibitors and beyond.

Authors:  Julian A Marin-Acevedo; ErinMarie O Kimbrough; Yanyan Lou
Journal:  J Hematol Oncol       Date:  2021-03-19       Impact factor: 17.388

Review 2.  Semaphorins as Potential Immune Therapeutic Targets for Cancer.

Authors:  Jun Jiang; Fang Zhang; Yi Wan; Ke Fang; Ze-Dong Yan; Xin-Ling Ren; Rui Zhang
Journal:  Front Oncol       Date:  2022-01-27       Impact factor: 6.244

Review 3.  Immune Regulatory Processes of the Tumor Microenvironment under Malignant Conditions.

Authors:  Katrin Pansy; Barbara Uhl; Jelena Krstic; Marta Szmyra; Karoline Fechter; Ana Santiso; Lea Thüminger; Hildegard Greinix; Julia Kargl; Katharina Prochazka; Julia Feichtinger; Alexander Ja Deutsch
Journal:  Int J Mol Sci       Date:  2021-12-10       Impact factor: 5.923
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.